US 7,498,034 B2
	Imaging, diagnosis and treatment of disease
Roy Bicknell, Birmingham (United Kingdom); and Lukasz Huminiecki, Cambridge (United Kingdom)
Assigned to Cancer Research Technology Limited, London (United Kingdom)
Appl. No. 10/416,090 PCT Filed Nov. 06, 2001, PCT No. PCT/GB01/04906 § 371(c)(1), (2), (4) Date Oct. 15, 2003, PCT Pub. No. WO02/36771, PCT Pub. Date May 10, 2002.
Prior Publication US 2004/0071711 A1, Apr. 15, 2004
Int. Cl. A61K 39/395 (2006.01); C07K 16/00 (2006.01)

U.S. Cl. 424—181.1  [424/178.1; 424/180.1; 424/182.1; 424/183.1; 530/391.1; 530/391.3; 530/391.7]

33 Claims

1. A compound comprising (i) an antibody which selectively binds to a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:37, and (ii) a further moiety, wherein the further moiety comprises a polypeptide, a directly cytotoxic chemotherapeutic agent, a directly cytotoxic polypeptide, a cytotoxic moiety which is able to convert a relatively non-toxic prodrug into a cytotoxic drug, or a radiosensitizer.